跳至主要内容
临床试验/NCT00519519
NCT00519519已完成3 期

Intravenous Infusion of High Dose Omeprazole Versus Regular Dose Omeprazole on Recurrent Bleeding After Endoscopic Treatment of Bleeding Peptic Ulcers

Singapore General Hospital2 个研究点 分布在 1 个国家目标入组 126 人开始时间: 2004年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
126
试验地点
2
主要终点
Re-bleeding rate after endoscopic treatment of bleeding peptic ulcers

研究概览

简要总结

Bleeding peptic ulcers are one of the major causes of morbidity and mortality for hospital emergency admissions.The initial treatment is endoscopic therapy followed by intravenous omeprazole. However the optimal dosage of omeprazole is not known. We conducted this study to find out the optimal dosage in such clinical scenario.

详细描述

Introduction

Peptic ulcer bleeding (PUB) is a common and life threatening condition. Intravenous infusion of high dose omeprazole (80mg as bolus followed by 8 mg/hr for 72 hours ie 652 mg/72 hrs) after endoscopic therapy resulted in greater reductions of re-bleeding than did placebo. Thus the above regime became our departmental protocol. However, there is some evidence that both high dose and a regular dose of omeprazole (40mg once a day followed by a saline infusion ie 120mg/72 hrs) would be equally effective. We calculated that high dose regimen is about S$ 500 more expensive. The aim of our study is to determine the equivalence of both regimes in preventing re-bleeding rate (primary end-point), surgery and mortality in PUB patients.

Study design This is a single institution prospective randomized double-blind study. All patient with PUB (Forrest classification I, IIa and IIb: spurting or oozing bleeding, visible vessels and clot) had endoscopic treatments (adrenaline injection and/or heater probe). After successful endoscopic hemostasis, patients are randomized to receive a high or regular dose of omeprazole infusion. After 72 hours, both groups of patients are given oral omeprazole 40mg daily for 4 weeks. All patients are evaluated at the clinic at the end of 4 weeks. The primary end-point is rebleeding. Other secondary endpoints measured are surgery, duration of hospital stay and death.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Above 21 year old
  • OGD done within 48 hrs of admission
  • No recent upper GIT surgery past one month
  • Forrest Type I, IIa & IIb ulcer (Type Ia: Spurting, Ib:Oozing, IIa: Visible vessel, IIb: Clot)
  • Non-malignant ulcer
  • Informed consent taken

排除标准

  • Impaired hepatic function
  • Concomitant medication (warfarin, diazepam, phenytoin, chlarithromycin, cimetidine and digoxin)
  • Underlying malignancy

研究组 & 干预措施

2

Active Comparator

regular dose versus high dose

干预措施: Omeprazole (Drug)

结局指标

主要结局

Re-bleeding rate after endoscopic treatment of bleeding peptic ulcers

时间窗: 30 days after endoscopic therapy

次要结局

  • Surgery, Death and Length of hospital stay(30 days after endoscopic thearpy)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验